169 related articles for article (PubMed ID: 36335580)
21. Systemic Mastocytosis with Associated Hematological Neoplasms. Diagnostic features and unique response pattern to tyrosine kinase inhibitors and allo-bone marrow transplantation therapy.
Hernández Alconchel I; González de Villambrosía S; Insunza Gaminde A; Montes Moreno S
Rev Esp Patol; 2023; 56(3):180-185. PubMed ID: 37419556
[TBL] [Abstract][Full Text] [Related]
22. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature.
Bernd HW; Sotlar K; Lorenzen J; Osieka R; Fabry U; Valent P; Horny HP
J Clin Pathol; 2004 Mar; 57(3):324-8. PubMed ID: 14990611
[TBL] [Abstract][Full Text] [Related]
23. Graft-versus-mastocytosis effect after donor lymphocyte infusion: Proof of principle.
Hägglund H; Yavuz AS; Dreimane A; Malm C; Sundin A; Sander B; Nilsson G
Eur J Haematol; 2021 Feb; 106(2):290-293. PubMed ID: 33010068
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
Liu B; Guo Y; Deng L; Qiao Y; Jian J
Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
[TBL] [Abstract][Full Text] [Related]
25. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia.
Nagai S; Ichikawa M; Takahashi T; Sato H; Yokota H; Oshima K; Izutsu K; Hangaishi A; Kanda Y; Motokura T; Chiba S; Yatomi Y; Kurokawa M
Exp Hematol; 2007 Nov; 35(11):1747-52. PubMed ID: 17976525
[TBL] [Abstract][Full Text] [Related]
26. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
Pullarkat ST; Wu W; Pullarkat V
Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
[TBL] [Abstract][Full Text] [Related]
27. Hodgkin's lymphoma is a rare form of clonal haematological non-mast cell disease in systemic mastocytosis.
Gasljevic G; Grcar-Kuzmanov B; Grosel A; Sever M; Gazic B; Kloboves-Prevodnik V
Diagn Pathol; 2015 Mar; 10():5. PubMed ID: 25881198
[TBL] [Abstract][Full Text] [Related]
28. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
[TBL] [Abstract][Full Text] [Related]
29. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
30. [Mastocytosis and eosinophilic leukemia: diagnostics and classification].
Sotlar K; Valent P; Horny HP
Pathologe; 2012 Nov; 33(6):539-52. PubMed ID: 23085697
[TBL] [Abstract][Full Text] [Related]
31. Acute myeloid leukemia (AML-M2) with mast cell hyperplasia of bone marrow: a report of three cases.
Adhya AK; Varma N; Varma S
Indian J Pathol Microbiol; 2007 Jul; 50(3):655-8. PubMed ID: 17883174
[TBL] [Abstract][Full Text] [Related]
32. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
33. Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity.
El Hussein S; Hu S; Fang H; Garces S; Muzzafar T; Wang SA; Medeiros LJ; Bueso-Ramos C; Jelloul FZ
Leuk Lymphoma; 2022 Jan; 63(1):235-238. PubMed ID: 34510998
[No Abstract] [Full Text] [Related]
34. Long-term Remission of Acute Myeloid Leukemia Developed From Systemic Mastocytosis by Conventional Chemotherapy.
Yamada A; Kinoshita M; Sawa D; Saito Y; Kamimura S; Miyachi H; Moritake H
J Pediatr Hematol Oncol; 2019 Aug; 41(6):e402-e404. PubMed ID: 30044348
[TBL] [Abstract][Full Text] [Related]
35. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone.
Pullarkat V; Bedell V; Kim Y; Bhatia R; Nakamura R; Forman S; Sun J; Senitzer D; Slovak ML
Leuk Res; 2007 Feb; 31(2):261-5. PubMed ID: 16876862
[TBL] [Abstract][Full Text] [Related]
36. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
[TBL] [Abstract][Full Text] [Related]
37. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis.
Sperr WR; Horny HP; Valent P
Int Arch Allergy Immunol; 2002 Feb; 127(2):140-2. PubMed ID: 11919425
[TBL] [Abstract][Full Text] [Related]
38. The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review.
Leguit R; Hebeda K; Kremer M; van der Walt J; Gianelli U; Tzankov A; Orazi A
Pathobiology; 2020; 87(1):2-19. PubMed ID: 31802761
[TBL] [Abstract][Full Text] [Related]
39. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
[TBL] [Abstract][Full Text] [Related]
40. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
Kluin-Nelemans HC; Jawhar M; Reiter A; van Anrooij B; Gotlib J; Hartmann K; Illerhaus A; Oude Elberink HNG; Gorska A; Niedoszytko M; Lange M; Scaffidi L; Zanotti R; Bonadonna P; Perkins C; Elena C; Malcovati L; Shoumariyeh K; von Bubnoff N; Müller S; Triggiani M; Parente R; Schwaab J; Kundi M; Fortina AB; Caroppo F; Brockow K; Zink A; Fuchs D; Angelova-Fischer I; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Simonowski A; Sabato V; Schug T; Jentzsch M; Breynaert C; Várkonyi J; Kennedy V; Hermine O; Rossignol J; Arock M; Valent P; Sperr WR
Theranostics; 2021; 11(1):292-303. PubMed ID: 33391475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
